TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30773022

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 18139

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 18139
Study: 27078990

Group type: EXPERIMENTAL
Intervention: Jianpi Liqi Yiliu Formula (JLYF) combined with cytokine‐induced killer (CIK) cells treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cytokine‐induced killer (CIK) cells treatment
Number of subjects: 60
Study: 25263143

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock-wave therapy (1 application with 1000 impulses at 0.19 to 0.23 mJ per square millimeter)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (deactivated shock-wave applicator and acoustic sham)
Number of subjects: 30
Study: 22047909

Group type: EXPERIMENTAL
Intervention: Two portions of farmed salmon weekly (n=47)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Normal diet low in fish (n=41)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Both salmon and control groups
Number of subjects: 88
Study: 19530746

Group type: EXPERIMENTAL
Intervention: Sotalol 160 mg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Sotalol 320 mg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 39
Study: 17697301

Group type: EXPERIMENTAL
Intervention: Buccal midazolam (0.2 mg/kg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Nitrous oxide/oxygen (30%/70%)
Number of subjects: 36
Study: 15705728

Group type: EXPERIMENTAL
Intervention: Six sessions of sprint interval training (SIT) over 2 weeks with 1-2 days rest between sessions
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (n = 8)
Number of subjects: 8
Study: 12119852

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 9852446

Group type: EXPERIMENTAL
Intervention: Stents placed above the sphincter of Oddi
Number of subjects: 34

Group type: COMPARATOR
Intervention: Stents placed across the sphincter of Oddi
Number of subjects: 34
Study: 8034814

Group type: EXPERIMENTAL
Intervention: Mediation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Litigation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mediation and Litigation
Number of subjects: 0
Study: 3058407

Group type: EXPERIMENTAL
Intervention: Subhepatic drain
Number of subjects: 200

Group type: COMPARATOR
Intervention: Nasogastric tube
Number of subjects: 200

Group type: COMPARATOR
Intervention: Postoperative iv-infusions
Number of subjects: 200
Study: 26976433

Group type: EXPERIMENTAL
Intervention: Bystander education program
Number of subjects: 969

Group type: EXPERIMENTAL
Intervention: Traditional awareness education program
Number of subjects: 969

Group type: COMPARATOR
Intervention: No education control group
Number of subjects: 969
Study: 28752410

Group type: EXPERIMENTAL
Intervention: Infection (serious infections post-stroke)
Number of subjects: 4011

Group type: COMPARATOR
Intervention: No infection
Number of subjects: 4011
Study: 25160009

Group type: EXPERIMENTAL
Intervention: FACETS programme (group-based fatigue management programme)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Multiple Sclerosis-Fatigue Self-Efficacy scale (8-item)
Number of subjects: 164
Study: 23832605

Group type: EXPERIMENTAL
Intervention: BDNF gene polymorphisms (rs6265, rs12273539, rs10835210)
Number of subjects: 709

Group type: EXPERIMENTAL
Intervention: Haplotype rs6265 (A)-rs12273539 (C)-rs10835210 (A)
Number of subjects: 709
Study: 21498062

Group type: EXPERIMENTAL
Intervention: IV tramadol 2.0 mg/kg
Number of subjects: 70

Group type: COMPARATOR
Intervention: Tramadol infiltration at trocar sites 2.0 mg/kg in 20 mL of 0.9% NaCl
Number of subjects: 70
Study: 18636958

Group type: EXPERIMENTAL
Intervention: Atazanavir 400 mg per day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lopinavir-ritonavir 400 mg and 100 mg twice per day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All groups (Atazanavir, Lopinavir-ritonavir, Placebo)
Number of subjects: 30
Study: 17030655

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid treatment (1.7 g of docosahexaenoic acid and 0.6 g of eicosapentaenoic acid daily)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study: 12918865

Group type: EXPERIMENTAL
Intervention: Elbow taping technique
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 16
Study: 11222823

Group type: EXPERIMENTAL
Intervention: Thrombolysis with rtPA given within six hours of stroke onset
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 9734743

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1.5 g/d)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study: 8283290

Group type: EXPERIMENTAL
Intervention: L. GG yogurt (2 x 150 mL/d, containing 10(11) cfu/L of L. GG)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: L. GG yogurt with rye fiber product (30 g/d, equivalent to 9 g fiber/d)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo yogurt and fiber
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: L. GG yogurt (with or without fiber)
Number of subjects: 64
Study: 2538676

Group type: EXPERIMENTAL
Intervention: Ketoconazole (1000 mg over 24 h) - short-term treatment
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Ketoconazole (600 mg/die for 1 week up to 12 months) - long-term treatment
Number of subjects: 14
Study: 31977371

Group type: EXPERIMENTAL
Intervention: 2 mL of 10 mg nalbuphine with 18 mL of 100 mg ropivacaine
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 2 mL of 20 mg nalbuphine with 18 mL of 100 mg ropivacaine
Number of subjects: 90

Group type: COMPARATOR
Intervention: 2 mL of normal saline with 18 mL of 100 mg ropivacaine
Number of subjects: 90
Study: 31367958

Group type: EXPERIMENTAL
Intervention: Hypoglycaemic clamp (plasma glucose 3.0 ± 0.2 mmol/l)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Euglycaemic clamp (plasma glucose 6.0 ± 0.2 mmol/l)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Hypoglycaemic clamp
Number of subjects: 25
Study: 28152542

Group type: EXPERIMENTAL
Intervention: RMI/RCOG
Number of subjects: 148

Group type: COMPARATOR
Intervention: SRMP
Number of subjects: 148
Study: 26561621

Group type: EXPERIMENTAL
Intervention: High carbohydrate intake (median: 238 g/d)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Low carbohydrate intake (median: 188 g/d)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Maternal intake of digestible carbohydrates in late pregnancy
Number of subjects: 222
Study: 22682526

Group type: EXPERIMENTAL
Intervention: E5 (five exposures to fruit)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: E5+ (five plus exposures to fruit)
Number of subjects: 95

Group type: COMPARATOR
Intervention: E1 (one exposure to fruit)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: E5 and E5+ (comparison between groups)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Repeated exposure interventions
Number of subjects: 95
Study: 21653735

Group type: EXPERIMENTAL
Intervention: GH substitution (9-12 months, placebo controlled)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GH/IGF1 stimulation in hFOB (osteoblasts)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GH/IGF1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IGF1 presence with SFLLRN stimulation
Number of subjects: 0
Study: 19361304

Group type: EXPERIMENTAL
Intervention: Subunit vaccine
Number of subjects: 304

Group type: COMPARATOR
Intervention: Virosomal vaccine
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Subunit vaccine (among HIV-infected patients)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Virosomal vaccine (among HIV-infected patients)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Subunit vaccine (among renal transplant patients)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Virosomal vaccine (among renal transplant patients)
Number of subjects: 304
Study: 16625311

Group type: EXPERIMENTAL
Intervention: 5 mg of solifenacin once daily
Number of subjects: 1873

Group type: EXPERIMENTAL
Intervention: 10 mg of solifenacin once daily
Number of subjects: 1873

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1873
Study: 16997737

Group type: EXPERIMENTAL
Intervention: 120 mg imMP with placebo tablets
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo injection with prednisolone 30 mg daily
Number of subjects: 27
Study: 11704123

Group type: EXPERIMENTAL
Intervention: Micronized 17beta‐E(2), 2 mg/day orally (cycle days 1 to 28)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Micronized 17beta‐E(2), administered vaginally (cycle days 1 to 28)
Number of subjects: 39
Study: 9191528

Group type: EXPERIMENTAL
Intervention: Methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Granulocyte-colony stimulating factor (G-CSF)
Number of subjects: 27
Study: 8106156

Group type: EXPERIMENTAL
Intervention: 175 mg/m2 TAXOL administered by 3-h infusion
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: 135 mg/m2 TAXOL administered by 3-h infusion
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: 175 mg/m2 TAXOL administered by 24-h infusion
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: 135 mg/m2 TAXOL administered by 24-h infusion
Number of subjects: 407
Study: 31094248

Group type: EXPERIMENTAL
Intervention: WUV5%
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: WUV10%
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: WUV15%
Number of subjects: 19

Group type: COMPARATOR
Intervention: Unloaded condition (control)
Number of subjects: 19
Study: 30736841

Group type: EXPERIMENTAL
Intervention: i-gel supraglottic airway device
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Tracheal intubation
Number of subjects: 1500
Study: 28653869

Group type: EXPERIMENTAL
Intervention: Neuromuscular exercise (NEMEX) program; 8-week, twice-weekly program consisting of 11 exercises with 3 to 4 levels of difficulty
Number of subjects: 23
Study: 26293146

Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Metformin 500 mg
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 23500230

Group type: EXPERIMENTAL
Intervention: Inclacumab 20 mg/kg
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Inclacumab 5 mg/kg
Number of subjects: 544

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 544
Study: 21457056

Group type: EXPERIMENTAL
Intervention: Self-regulation counseling delivered by cell phone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual care (control condition)
Number of subjects: 40
Study: 18212288

Group type: COMPARATOR
Intervention: Gadoversetamide 0.05, 0.1, 0.2, or 0.3 mmol/kg
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: Gadoversetamide doses > or = 0.2 mmol/kg
Number of subjects: 566
Study: 17013851

Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Range-of-Motion (ROM)
Number of subjects: 221
Study: 12728756

Group type: EXPERIMENTAL
Intervention: Group visits
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 120
Study: 11303311

Group type: EXPERIMENTAL
Intervention: Glucocorticosteroids (gcs), total dose equivalent to prednisone 7.4 ± 8.3 g
Number of subjects: 90

Group type: COMPARATOR
Intervention: No treatment with glucocorticosteroids (gcs)
Number of subjects: 90
Study: 8619449

Group type: EXPERIMENTAL
Intervention: Pyronaridine 1,200 mg over a three-day period (Group I)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Pyronaridine 1,800 mg over a five-day period (Group II)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: In vitro drug sensitivity tests
Number of subjects: 101
Study: 1463951

Group type: EXPERIMENTAL
Intervention: Paracetamol plus unwrapping
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Warm sponging plus unwrapping
Number of subjects: 52

Group type: COMPARATOR
Intervention: Unwrapping alone
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Warm sponging
Number of subjects: 52
Study: 6363434

Group type: EXPERIMENTAL
Intervention: Dihydrotestosterone (DHT) 125 mg twice daily for 10 days
Number of subjects: 12
Study: 31688451

Group type: EXPERIMENTAL
Intervention: PF-02545920 5 mg Q12H
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: PF-02545920 15 mg Q12H
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Risperidone 3 mg Q12H
Number of subjects: 259

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 259
Study: 29905383

Group type: EXPERIMENTAL
Intervention: Guselkumab 50 mg
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg
Number of subjects: 192

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study: 27271613

Group type: EXPERIMENTAL
Intervention: Fuzheng-Huayu (FZHY) formula
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: miRNA panel (hsa-miR-18a-5p, -326, -1182, -193b-5p)
Number of subjects: 0
Study: 25358527

Group type: EXPERIMENTAL
Intervention: DASH (Disabilities of the Arm, Shoulder and Hand)
Number of subjects: 153
Study: 22291101

Group type: EXPERIMENTAL
Intervention: Zoster vaccine (ZV) (Zostavax; Merck)
Number of subjects: 22439

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22439

Group type: EXPERIMENTAL
Intervention: Zoster vaccine (ZV)
Number of subjects: 22439
Study: 20818269

Group type: EXPERIMENTAL
Intervention: Maize after phytate reduction for 40 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Habitual maize‐based high‐phytate diet
Number of subjects: 10
Study: 17415555

Group type: EXPERIMENTAL
Intervention: Flexible cystoscopy + midazolam
Number of subjects: 80

Group type: COMPARATOR
Intervention: Flexible cystoscopy + no midazolam
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Rigid cystoscopy + midazolam
Number of subjects: 80

Group type: COMPARATOR
Intervention: Rigid cystoscopy + no midazolam
Number of subjects: 80
Study: 15642565

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simvastatin 40 mg
Number of subjects: 0
Study: 11856079

Group type: EXPERIMENTAL
Intervention: Balsalazide, 6.75 g daily
Number of subjects: 57

Group type: COMPARATOR
Intervention: Sulfasalazine, 3 g daily
Number of subjects: 57
Study: 9659868

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 8134222

Group type: EXPERIMENTAL
Intervention: Acetaminophen (15 mg/kg per dose, 0.15 mL/kg per dose) every 6 hours for 24 hours
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (0.15 mL/kg per dose) every 6 hours for 24 hours
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Acetaminophen and Placebo (both groups)
Number of subjects: 44
Study: 2504359

Group type: EXPERIMENTAL
Intervention: Written invitations to have a smear taken
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Notes tagged for doctor reminders
Number of subjects: 416

Group type: COMPARATOR
Intervention: No special intervention (Control group)
Number of subjects: 416
Study: 1168110

Group type: EXPERIMENTAL
Intervention: Hog mucosal heparin
Number of subjects: 24

Group type: COMPARATOR
Intervention: Beef lung heparin
Number of subjects: 24
Study: 31856476

Group type: EXPERIMENTAL
Intervention: Intraocular lens (IOL) implantation with optic capture through a primary posterior continuous curvilinear capsulorhexis (PPC) without vitrectomy
Number of subjects: 15

Group type: COMPARATOR
Intervention: Endocapsular IOL implantation with PPC and anterior vitrectomy
Number of subjects: 15
Study: 31135550

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (enoxaparin 40 mg or dalteparin 5000 IUs daily)
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Chemoprophylaxis (various types including aspirin and warfarin)
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Symptomatic VTE
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Overall patient population
Number of subjects: 637
Study: 28406882

Group type: EXPERIMENTAL
Intervention: Educational support (ES) group - additional polysomnography chart viewing from both diagnostic and titration nights
Number of subjects: 115

Group type: COMPARATOR
Intervention: Standard support (SS) group - general information about OSA and PAP treatment at baseline
Number of subjects: 115
Study: 25468670

Group type: EXPERIMENTAL
Intervention: 15% Cypermethrin + 30% Chlorpyriphos + 15% Fenthion‐Colosso(®) FC 30
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 60% Dichlorvos + 20% Chlorpyriphos‐Ectofós(®)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Field trials with naturally infected animals
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stall Tests using artificially infested cattle
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adult Immersion Tests (AIT)
Number of subjects: 0
Study: 23500298

Group type: EXPERIMENTAL
Intervention: Electrical cardioversion (ECV)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Pharmacologic cardioversion (PCV)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Overall incidence of ECV, PCV, or AF ablation
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Stroke or systemic embolism
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Death
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Hospitalization after cardioversion or AF ablation
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Long-term incidence of stroke or systemic embolism
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Cardiovascular death
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Death from all causes
Number of subjects: 321
Study: 21749677

Group type: EXPERIMENTAL
Intervention: MDFT (Multidimensional Family Therapy)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 450
Study: 19459997

Group type: EXPERIMENTAL
Intervention: Trospium chloride 60 mg extended release (XR)
Number of subjects: 1165

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1165
Study: 16702250

Group type: EXPERIMENTAL
Intervention: Microstream capnography monitoring
Number of subjects: 163

Group type: COMPARATOR
Intervention: Routine care with 2-L supplemental oxygen via nasal cannula and capnography monitoring for >60 seconds
Number of subjects: 163
Study: 12669751

Group type: EXPERIMENTAL
Intervention: Apparent motion used to define high-level representation associated with the target.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Initial display followed by a second display with masks appearing at new locations.
Number of subjects: 0
Study: 10722180

Group type: EXPERIMENTAL
Intervention: Quetiapine (mean total daily dose 455 mg)
Number of subjects: 448

Group type: COMPARATOR
Intervention: Haloperidol (mean total daily dose 8 mg)
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 448

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 448
Study: 8615421

Group type: EXPERIMENTAL
Intervention: Valproate and valproate plus lithium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carbamazepine and carbamazepine plus lithium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lithium monotherapy
Number of subjects: 0
Study: 1399665

Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Nondependent position (right lateral)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Dependent position (left lateral)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Age correlation with PaO2
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Degree of atelectasis correlation with change in PaO2
Number of subjects: 25
Study: 4040552

Group type: EXPERIMENTAL
Intervention: Metoclopramide (IV, 2 mg/kg over 15 minutes, given 30 minutes before, 30 minutes after, and three hours after cisplatin)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Prochlorperazine (IV, given 30 minutes before and three hours after cisplatin; placebo at 30 minutes after cisplatin)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Overall incidence of adverse reactions
Number of subjects: 60
Study: 31039052

Group type: COMPARATOR
Intervention: Camrelizumab monotherapy (200 mg)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Decitabine (10 mg/d, days 1 to 5) plus camrelizumab (200 mg, day 8)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Decitabine plus camrelizumab
Number of subjects: 86
Study: 28483191

Group type: EXPERIMENTAL
Intervention: Acupressure at the Zusanli (ST-36) acupoint for 30 minutes per visit for 11 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Regular treatment (control group)
Number of subjects: 30
Study: 25566730

Group type: EXPERIMENTAL
Intervention: Nasal salmon calcitonin (NSC) 200 IU/day
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Nasal salmon calcitonin (NSC)
Number of subjects: 90
Study: 24722500

Group type: EXPERIMENTAL
Intervention: Imeglimin (1,500 mg b.i.d.)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study: 23102076

Group type: EXPERIMENTAL
Intervention: 0.2% glyceryl trinitrate (GTN) ointment
Number of subjects: 210

Group type: COMPARATOR
Intervention: Routine postoperative management (Control)
Number of subjects: 210
Study: 19403710

Group type: EXPERIMENTAL
Intervention: Iron deficiency (plasma ferritin <12 microg/L or transferrin receptor >4.4 mg/L)
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Anemia (hemoglobin <120 g/L)
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Folate deficiency (plasma folate <or=10 nmol/L)
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Iron deficiency and anemia
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Iron stores
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Risk of anemia among nonstudents
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Risk of anemia among women with previous miscarriage
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Risk of anemia among iron-deficient women
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Mean plasma ferritin concentration in adolescents (<or=19 y)
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Body iron stores in adolescents (<or=19 y)
Number of subjects: 272
Study: 17970235

Group type: EXPERIMENTAL
Intervention: Organic foods (fruits, vegetables, red wine, milk)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Mediterranean organic diet for 14 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional foods (fruits, vegetables, red wine, milk)
Number of subjects: 10